Remimazolam besylate; overview of a novel benzodiazepine for general anesthesia

Remimazolam, a novel, ultra-short-acting intravenous anesthetics, belongs to the benzodiazepine class of drugs and was approved for as general anesthetic. Its pharmacological action is similar that midazolam. However, differences in metabolic pathway pharmacokinetic profiles its metabolites contribute faster offset remimazolam than The context-sensitive half time (CSHT) short 6.8 ± 2.4 min. An advantage over other such propofol, presence antagonists. Remimazolam-induced sedation reversed by flumazenil, antagonist. Moreover, lower prevalence injection site pain less reduction blood pressure are advantages propofol. Although our knowledge limited at present, may be useful anesthesia. We look forward future possibilities this new anesthetic agent.
 Key words: Anesthesia, General; Intravenous; Benzodiazepine; Remimazolam
 Citation: Morimoto Y. Remimazolam besylate; overview novel Anaesth. intensive care 2022;26(3):277-279; DOI: 10.35975/apic.v26i3.1819
 Received: February 01, 2022; Reviewed: May 04, Accepted: 07, 2022